PRECLINICAL EVALUATION OF PROTOTYPE 21- AND 25-GAUGE SAMPLING NEEDLES USING A THIN CONVEX PROBE ENDOBRONCHIAL ULTRASOUND

Abstract

SESSION TITLE: Rapid: Diagnostic and Therapeutic Interventions in Lung Cancer SESSION TYPE: Original Investigations PRESENTED ON: 10/21/2019 1:30 PM - 2:30 PM PURPOSE: A prototype thin convex probe endobronchial ultrasound (TCP-EBUS) was previously found to improve access to distal airways compared with current CP-EBUS1. The aim of this study was to assess prototype 21-gauge and 25-gauge (21G and 25G, respectively) needles designed for this TCP-EBUS for sampling of peripheral and middle lung malignancies in ex vivo human lungs. METHODS: EBUS-guided transbronchial needle aspiration (EBUS-TBNA) was performed using a prototype TCP-EBUS (BF-Y0086; Olympus, Tokyo, Japan) with 21G and 25G needles (Olympus) in resected human lung specimens from patients with lung cancer. The 21G followed by 25G needles were used sequentially for the same lesions in a similar fashion by the same surgeon. The adequacy of the TBNA sample was evaluated based on cellularity and blood contamination by a cytopathologist. Cytological diagnosis for each TBNA sample was similarly determined by a cytopathologist. The diagnostic yield was compared between the 21G and 25G samples based on corresponding final surgical pathology from the related lung specimen. RESULTS: Twelve resected human lung specimens (lobectomy, n = 11; segmentectomy, n = 1) from 12 patients with lung cancer were evaluated in this study. The mean long axis of the tumors biopsied by EBUS-TBNA was 27.8 ± 9.9 mm measured by preoperative computed tomography images. Six lung tumors were located in the peripheral-third of the lung, and the other six were located in the middle-third of the lung. Final surgical pathology confirmed malignancy in all cases (adenocarcinoma, n = 10; small cell carcinoma, n = 1; large cell carcinoma, n = 1). Sample adequacy (as defined by high cellularity with low blood contamination) was 91.6% (11/12 samples) with both the 21G and 25G needles. Concordant cytological and final pathological diagnosis was obtained in 81.8% (9/11 samples) of the 21G samples and 90.9% (10/11 samples) of the 25G samples. CONCLUSIONS: TCP-EBUS, combined with a prototype 21G and/or 25G TBNA needle, could access and accurately sample peripheral and middle lung tumors in ex vivo human lung specimens. Both needles performed similarly. CLINICAL IMPLICATIONS: The TCP-EBUS with either the 21-gauge or 25-gauge needles might be feasible for the diagnosis of middle and peripheral lung malignancies in human lungs. DISCLOSURES: No relevant relationships by Nicholas Bernards, source=Web Response No relevant relationships by Zhenchian Chen, source=Admin input No relevant relationships by Andrew Effat, source=Web Response No relevant relationships by Alexander Gregor, source=Web Response No relevant relationships by Terunaga Inage, source=Web Response No relevant relationships by TSUKASA ISHIWATA, source=Web Response Speaker/Speaker's Bureau relationship with Olympus Please note: $1001 - $5000 Added 03/14/2019 by Schwock Joerg, source=Admin input, value=Honoraria Speaker/Speaker's Bureau relationship with Merck Please note: $1001 - $5000 Added 03/14/2019 by Schwock Joerg, source=Admin input, value=Honoraria No relevant relationships by Tomonari Kinoshita, source=Web Response No relevant relationships by Yamato Motooka, source=Web Response No relevant relationships by Hideki Ujiie, source=Web Response research support relationship with Olympus Corporation Please note: $5001 - $20000 Added 03/14/2019 by Kazuhiro Yasufuku, source=Web Response, value=Grant/Research Consultant relationship with Olympus America Inc Please note: $1001 - $5000 Added 03/14/2019 by Kazuhiro Yasufuku, source=Web Response, value=Consulting fee Consultant relationship with Medtronic Please note: $1001 - $5000 Added 03/14/2019 by Kazuhiro Yasufuku, source=Web Response, value=Consulting fee Consultant relationship with Johnson and Johnson Please note: $1001 - $5000 Added 03/14/2019 by Kazuhiro Yasufuku, source=Web Response, value=Consulting fee Consultant relationship with Auris Surgical Robotics Please note: $1001 - $5000 Added 03/14/2019 by Kazuhiro Yasufuku, source=Web Response, value=Consulting fee Speaker/Speaker's Bureau relationship with Pfizer Inc Please note: $5001 - $20000 Added 03/15/2019 by Ichiro Yoshino, source=Admin input, value=Honoraria Speaker/Speaker's Bureau relationship with Shionogi & Co., Ltd Please note: $5001 - $20000 Added 03/15/2019 by Ichiro Yoshino, source=Admin input, value=Honoraria Speaker/Speaker's Bureau relationship with Astellas Pharma Inc Please note: $5001 - $20000 Added 03/15/2019 by Ichiro Yoshino, source=Admin input, value=Honoraria Speaker/Speaker's Bureau relationship with Nippon Boehringer Ingelheim Co., Ltd Please note: $5001 - $20000 Added 03/15/2019 by Ichiro Yoshino, source=Admin input, value=Honoraria Speaker/Speaker's Bureau relationship with Daiichi Sankyo Company, Limited Please note: $5001 - $20000 Added 03/15/2019 by Ichiro Yoshino, source=Admin input, value=Honoraria Speaker/Speaker's Bureau relationship with Chugai Pharmaceutical Co., Ltd Please note: $5001 - $20000 Added 03/15/2019 by Ichiro Yoshino, source=Admin input, value=Honoraria Speaker/Speaker's Bureau relationship with Ono Pharmaceutical Co., Ltd Please note: $5001 - $20000 Added 03/15/2019 by Ichiro Yoshino, source=Admin input, value=Honoraria Speaker/Speaker's Bureau relationship with Teijin Pharma Limited Please note: $5001 - $20000 Added 03/15/2019 by Ichiro Yoshino, source=Admin input, value=Honoraria